Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:acquiredBy |
gptkb:Allergan
|
| gptkbp:alsoKnownAs |
deoxycholic acid
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:Health_Canada |
| gptkbp:brand |
gptkb:Kybella
gptkb:Belkyra |
| gptkbp:chemicalClass |
bile acid
|
| gptkbp:contraindication |
dysphagia
infection at injection site |
| gptkbp:developedBy |
gptkb:Kythera_Biopharmaceuticals
|
| gptkbp:hasMolecularFormula |
C24H40O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
ATX-101
|
| gptkbp:indication |
cosmetic treatment
double chin reduction |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
disrupts adipocyte cell membranes
|
| gptkbp:routeOfAdministration |
injection
|
| gptkbp:sideEffect |
hardness
numbness pain at injection site redness swelling bruising |
| gptkbp:usedFor |
reduction of submental fat
|
| gptkbp:bfsParent |
gptkb:Kybella
|
| gptkbp:bfsLayer |
8
|